Phase II Trial of M6620 and Gemcitabine in Recurrent Ovarian Cancer
A phase II trial is evaluating the efficacy of ATR kinase inhibitor M6620 combined with gemcitabine hydrochloride in recurrent ovarian cancer.
Asset / Drug
Drug and asset intelligence for Phase with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.